DcR3 polypeptide, a TNFR homolog
AssigneeGenentech, Inc.
InventorsAvi J. Ashkenazi, David Botstein, Kelly H. Dodge, Audrey Goddard, Austin L. Gurney, Kyung Jin Kim, David A. Lawrence, Robert Pitti, Margaret A. Roy, Daniel B. Tumas, William I. Wood
Life of this patent
Estimating the term…
Abstract
A TNFR homolog, identified as DcR3, is provided. Nucleic acid molecules encoding DcR3, chimeric molecules and antibodies to DcR3 are also provided.
Claims66
An isolated DcR3 polypeptide having at least about 80% amino acid sequence identity with native sequence DcR3 polypeptide comprising amino acid residues 1 to 300 of FIG. 1 (SEQ ID NO:1).
An isolated native sequence DcR3 polypeptide comprising amino acid residues 1 to 300 of FIG. 1 (SEQ ID NO:1).
An isolated DcR3 polypeptide comprising amino acid residues 1 to 215 of FIG. 1 (SEQ ID NO:1).
An isolated DcR3 polypeptide comprising amino acid residues 1 to X, wherein X is any one of amino acid residues 215 to 300 of FIG. 1 (SEQ ID NO:1).
An isolated TNFR homolog comprising a polypeptide which includes one or more cysteine rich domains, wherein said one or more cysteine rich domains comprises the amino acid sequence of CRD1, CRD2, CDR3 or CRD4 shown in FIG. 6.
The hybridoma cell line 4C4.1.4 deposited as ATCC accession number ______.
The hybridoma cell line 5C4.14.7 deposited as ATCC accession number ______.
The hybridoma cell line 11C5.2.8 deposited as ATCC accession number ______.
The hybridoma cell line 8D3.1.5 deposited as ATCC accession number ______.
The hybridoma cell line 4B7.1.l deposited as ATCC accession number ______.
The 4C4.1.4 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number ______.
The 5C4.14.7 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number ______.
The 11C5.2.8 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number ______.
The 8D3.1.5 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number ______.
The 4B7.1.1 monoclonal antibody produced by the hybridoma cell line deposited as ATCC accession number ______.
A non-human, transgenic animal which contains cells that express nucleic acid encoding DcR3 polypeptide.
A non-human, knockout animal which contains cells having an altered gene encoding DcR3 polypeptide.
An article of manufacture, comprising a container and a composition contained within said container, wherein the composition includes DcR3 polypeptide or DcR3 antibodies.
A method of modulating apoptosis in mammalian cells comprising exposing said cells to DcR3 polypeptide or a chimeric molecule comprising DcR3 polypeptide.
A method of inhibiting Fas ligand induced apoptosis in mammalian cells comprising exposing said cells to DcR3 polypeptide or a chimeric molecule comprising DcR3 polypeptide.
A method of inhibiting Fas ligand induced activity in mammalian cells comprising exposing said cells to DcR3 polypeptide or a chimeric molecule comprising DcR3 polypeptide.
A method of treating mammalian cancer comprising exposing mammalian cancer cells to DcR3 antibodies.
A method of detecting or diagnosing cancer in a mammal comprising analyzing mammalian cells for amplification of a DcR3 gene.
A method of inhibiting a T-cell mediated immune response in a mammal, comprising exposing mammalian cells to DcR3 polypeptide or a chimeric molecule comprising DcR3 polypeptide.
An isolated nucleic acid comprising the nucleotide sequence of SEQ ID NO:3 or its complement.
Dependencies are inferred from the claim text.